(Q50537326)

English

The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.

scientific article published on 26 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

The effect of sunitinib on immune subsets in metastatic clear cell renal cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

author name string

Thomas Powles

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Simon Chowdhury

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Nataile Saunders

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Louise Lim

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Jonathan Shamash

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Naveed Sarwar

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Anju Sadev

8

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

John Peters

9

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

James Green

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Katia Boleti

11

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Samir Augwal

12

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

publication date

26 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Urologia Internationalis

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

86

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

53-59

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Immunotherapy of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1159%2F000319498

21 January 2018

Identifiers

10.1159/000319498

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20975250

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50537326&oldid=839159821"